Ex-Ed­i­tas CEO Ka­trine Bosley chairs Ar­rakis board; Car­du­ri­on touts Po­laris in­vest­ment

→ Af­ter a sur­prise ex­it from Ed­i­tas Med­i­cine in Jan­u­ary — which left many in shock and the stock plung­ing 21% $ED­IT — ex-CEO Ka­trine Bosley will be head­ing the board of di­rec­tors at Michael Gilman-led Ar­rakis Ther­a­peu­tics as chair­man. She is al­so a board mem­ber of Gala­pa­gos and Geno­cea Bio­sciences.

→ Car­du­ri­on Phar­ma­ceu­ti­cals — fo­cused on the treat­ment of heart fail­ure and oth­er car­dio­vas­cu­lar dis­eases — has com­plet­ed a pri­vate in­vest­ment from Po­laris Part­ners. Po­laris joined ex­ist­ing in­vestor Take­da in back­ing the start­up and is send­ing its man­ag­ing part­ner Amy Schul­man to the board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER